tbuckley/cabot-search huggingface dataset:
Complete remission in three patients with acute myeloblastic leukemia by administration of G‐CSF without antileukemic agents
Authors: Masuhiro Takahashi, Tadashi Koike, Yoshifusa Aizawa, Makoto Kashimura, Kunihiro Hayatsu, Ko‐ichi Nagai, Atsushi Abe, Masaru Urushiyama, Kumiko Yagisawa
Journal: American Journal of Hematology (1997)

We describe 3 patients with acute myeloblastic leukemia (AML), who received rhG-CSF for infections such as pneumonia or for prophylaxis of infection, and who achieved complete remission. They had not received any antileukemic therapy before or during the administration of rhG-CSF. These findings suggest the possibility that complete remission can be brought about by G-CSF itself in some patients with AML. Am. J. Hematol. 56:42–44, 1997. © 1997 Wiley-Liss, Inc.
Association of acetaminophen hepatotoxicity with fasting and ethanol use
Authors: D. C. Whitcomb
Journal: JAMA (1994)

<h3>Objectives.</h3> —To evaluate the association of fasting and alcohol use with hepatotoxicity from acetaminophen ingested for therapeutic reasons. <h3>Design.</h3> —Retrospective case series. <h3>Setting.</h3> —Hospitals of the University of Pittsburgh (Pa) Medical Center. <h3>Patients.</h3> —A total of 126779 discharge summaries from January 1987 to July 1993 were reviewed using a comprehensive, whole-text-indexed medical database to identify all patients with acetaminophen ingestion and hepatotoxicity. These patients were categorized according to the intended acetaminophen use and dose of acetaminophen ingested. <h3>Main Outcomes Measured.</h3> —The independent variables of chronic alcohol use, recent alcohol use, and recent fasting were determined for all patients. <h3>Results.</h3> —Forty-nine patients with acetaminophen hepatotoxicity (aspartate aminotransferase &gt;1000 U/L) were identified. Twenty-one patients (43%) ingested acetaminophen for therapeutic purposes. All patients with hepatotoxicity took more than the recommended limit of 4 g/d. Recent fasting was more common than recent alcohol use among those who suffered hepatotoxicity after a dose of 4 to 10 g of acetaminophen per day (<i>P</i>=.02). Recent alcohol use was more common in the group who took more than 10 g/d than in those who took 4 to 10 g/d (<i>P</i>=.004). <h3>Conclusion.</h3> —Acetaminophen hepatotoxicity after a dose of 4 to 10 g/d was associated with fasting and less commonly with alcohol use. Patients who developed hepatoxicity after taking acetaminophen doses of greater than 10 g/d for therapeutic purposes were alcohol users. Acetaminophen hepatotoxicity after an overdose appears to be enhanced by fasting in addition to alcohol ingestion. (<i>JAMA</i>. 1994;272:1845-1850)
Highlights From the <i>Circulation</i> Family of Journals
Authors: Eoin Donnellan, Oussama Wazni, Mohamed Kanj, Ayman Hussein, Bryan Baranowski, Bruce Lindsay, Ali Aminian, Wael Jaber, Philip Schauer, Walid Saliba, Omar Batal, Saurabh Malhotra, Matthew Harinstein, Jeremy Markowitz, Gavin Hickey, Sunil Agarwal, Pamela Douglas, Prem Soman, Caroline Kramer, Sadia Mehmood, Renée Suen, Yasbanoo Moayedi, Chun Po, S Fan, Wida Cherikh, Joseph Stehlik, Jeffrey Teuteberg, Heather Ross, Kiran Khush
Journal: Circulation (2019)

Morbid obesity is a known risk factor for recurrent atrial fibrillation after ablation.In this singlecenter observational cohort study, the arrhythmia recurrence rates of morbidly obese patients who underwent bariatric surgery (BS) are compared with those who did not undergo BS, and with nonobese patients after atrial fibrillation ablation.BS was associated with a reduction in arrhythmia recurrence after ablation, with rates comparable with nonobese patients, raising the hypothesis that morbidly obese patients may benefit from BS before atrial fibrillation ablation for the prevention of recurrent atrial fibrillation.
Response: Re: Promoting Healthy Skepticism in the News: Helping Journalists Get It Right
Authors: L. M. Schwartz, S. Woloshin, B. S. Kramer
Journal: JNCI Journal of the National Cancer Institute (2011)

statistically significant"), results can still be very wrong: The study may be biased or confounded.For example, the observed difference in the 5-year risk of death between the drug and placebo groups is not consistent with chance alone (ie, P = .0004,there is only a 4 in 10 000 chance of seeing differences this big or bigger if drug and placebo were equally effective).
Chimeric antigen receptor (CAR) T cells genetically engineered to deliver IL-12 to the tumor microenvironment in ovarian cancer.
Authors: Oladapo O. Yeku, Terence Purdon, David R. Spriggs, Renier J. Brentjens
Journal: Journal of Clinical Oncology (2017)

3050 Background: Chimeric antigen receptor (CAR) T cell therapy for solid tumor malignancies has not shown the same degree of clinical efficacy observed in hematologic malignancies. The presence of an immunosuppressive cytokine and cellular microenvironment has been hypothesized as one reason for the failure of adoptive immunotherapy for solid tumors. In ovarian cancer, the presence of tumor associated macrophages (TAMs) and immunosuppressive cytokines in the ascitic microenvironment have been reported. IL-12 is a proinflammatory cytokine produced by macrophages, dendritic cells (DC) and NK cells, and has been shown to increase proliferation of T cells and enhance antigen presentation by macrophages. We hypothesized that CAR T cells genetically modified to constitutively secrete IL-12 would overcome a hostile tumor microenvironment in a peritoneal carcinomatosis model of ovarian cancer. Methods: CAR T cells were generated from retroviral transduction of second generation and IL-12 modified CAR’s directed to either an irrelevant CD-19 antigen or Muc16 ecto . Results: Here we report increased production of IL-12, improved proliferation and cytotoxic activity of 4H1128-IL12 CAR T cells. We show increased levels of inflammatory cytokines at 24 and 48hrs after treatment of tumor-bearing mice, leading to increased survival at advanced stages of disease. Mice treated with 4H1128-IL12 CAR T cells had decreased levels of F4/80 + CD11b + TAM’s. Genetic analysis of recovered TAM’s from the ascites of treated animals showed skewing towards an M1-phenotype via upregulation of cytokines, chemokines, MHC-II and downregulation of Arg1. Recovered 4H1128-IL12 CAR T cells showed upregulation of FAS-L and recovered TAMs showed increased expression of FAS suggesting FAS/FAS-L engagement was responsible for decreased TAMs. Blocking the FAS/FAS-L pathway led to recovery of TAM populations in 4H1128-IL12 treated mice. Finally, clodronate-mediated depletion of TAM’s further enhanced survival in mice treated with 4H1128-IL12 CAR T cells. Conclusions: These results demonstrate the mechanisms of efficacy of localized delivery of IL-12 to the tumor microenvironment by 4H1128-IL12 CAR T cells.
WORKING MODELS IN MEDICINE
Journal: JAMA (1960)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Ineffective epoprostenol therapy for thrombotic thrombocytopenic purpura
Authors: J. E. Johnson
Journal: JAMA (1983)

THROMBOTIC thrombocytopenic purpura (TTP) is an often fatal condition of unknown pathogenesis and uncertain therapy. We report herein the treatment of a patient with TTP with epoprostenol (prostacyclin) after her failure to respond to standard therapeutic modalities. Epoprostenol has been previously reported to be beneficial in this condition.<sup>1</sup>To our knowledge, this is the fourth patient to receive epoprostenol for TTP. <h3>Report of a Case</h3> A previously healthy 20-year-old woman was seen after a one-week history of fever, chills, nausea, and malaise. Her social history included occasional marijuana use and moderate alcohol intake, but no other use of medications or intravenous (IV) drug abuse. She stated that she had been bitten by a spider one week before admission. On examination, she was pale and diaphoretic; BP was 128/80 mm Hg; pulse rate, 134 beats per minute; respirations, 20/min; and rectal temperature, 38.9 °C. A fine, diffuse petechial rash, sparing
"THE ENDOSTEUM"
Authors: Leonard W. Ely
Journal: JAMA (1924)

<h3>To the Editor:</h3> —In my letter on this subject (The Journal, July 26, p. 289), that portion of it which asked for some concrete evidence of the existence of any such structure as an endosteum was elided, though it was the nubbin of the whole matter. Leaving this out, you publish Dr. Haas' erudite answer, giving various opinions and theories of different authorities, with a learned disquisition on the subject of bone formation in general. This whole matter illustrates well the great difficulty of establishing the treatment of diseases of bones and joints on a rational basis. We have little else but theories and opinions to guide us. Some eminent authority expresses an opinion. It is accepted as a fact, and perhaps an elaborate treatment is based on it. When we seek for a foundation of the treatment, we find that there is none. Perhaps, instead of asking for information,
Erratum: Thermoneutral housing exacerbates nonalcoholic fatty liver disease in mice and allows for sex-independent disease modeling
Authors: Daniel A Giles, Maria E Moreno-Fernandez, Traci E Stankiewicz, Simon Graspeuntner, Monica Cappelletti, David Wu, Rajib Mukherjee, Calvin C Chan, Matthew J Lawson, Jared Klarquist, Annika Sünderhauf, Samir Softic, C Ronald Kahn, Kerstin Stemmer, Yoichiro Iwakura, Bruce J Aronow, Rebekah Karns, Kris A Steinbrecher, Christopher L Karp, Rachel Sheridan, Shiva K Shanmukhappa, Damien Reynaud, David B Haslam, Christian Sina, Jan Rupp, Simon P Hogan, Senad Divanovic
Journal: Nature Medicine (2017)
Measles—United States, First 26 Weeks, 1987
Journal: JAMA (1988)

As of July 3, 1993 (week 26), local and state health departments had reported a provisional total of 167 measles cases for 1993--the lowest total reported for the first 26 weeks of any year since surveillance began in 1943 and a 99% decrease from the 13,787 cases reported during the first 26 weeks of 1990, the peak of the recent resurgence. Cases were reported from 18 states. This report summarizes the epidemiologic characteristics of measles cases reported for the first 26 weeks of 1993 and compares them with cases reported during 1989-1991.
Asthma And Airway Hyperresponsiveness
Authors: R. Ingram
Journal: Annual Review of Medicine (1991)

CD40 is a cell-surface member of the TNF (tumor necrosis factor) receptor superfamily. Upon activation, CD40 can license dendritic cells to promote antitumor T cell activation and re-educate macrophages to destroy tumor stroma. Numerous agonist CD40 ...Read More
Respiratory tract illness in meat wrappers
Authors: H. Falk
Journal: JAMA (1976)

A questionnaire survey was done in 152 Houston supermarkets to assess the prevalence of respiratory tract symptoms in meat wrappers exposed to the thermal decomposition fumes of polyvinyl chloride (PVC) film wrap and in two supermarket control groups (checkers and meat cutters). Meat wrappers had increased respiratory tract symptoms; 12% of meat wrappers who smoked (vs 6% and 2% of controls) and 5% of meat wrappers who did not smoke (vs 0% and 0% of controls) had multiple respiratory tract symptoms. It is probable that a large number of meat wrappers have mild symptoms with some progressing to more severe respiratory impairment or clinical asthma. (<i>JAMA</i>235:915-917, 1976)
13C-methacetine breath test for the prediction of liver damage caused by transarterial chemoembolization in patients with hepatocellular carcinoma
Authors: Stella Wellhöner, Florian Gerhardt, Albrecht Boehlig, Rami Al-Sayegh, Rhea Veelken, Bettina Maiwald, Steffen Strocka, Tim-Ole Petersen, Timm Denecke, Thomas Berg, Florian van Bömmel
Journal: Journal of Hepatology (2020)
Judge rules diversion of antismoking money illegal, victory for California Tobacco Control Program
Authors: A. A. Skolnick
Journal: JAMA (1995)

ANTISMOKING FORCES scored a decisive victory in the struggle to save California's highly acclaimed Tobacco Control Program. On January 23, Sacramento Superior Court Judge Roger K. Warren ordered the state of California to immediately stop spending tobacco taxes that were diverted from the program's antismoking education and research accounts. At issue is $128 million that the court determined had been illegally diverted from accounts set up by Proposition 99 (Prop 99). This public initiative, passed in 1988 by a vote of 58% to 42%, boosted the state's tobacco tax 25 cents per pack and required 5% of the revenues to be spent on tobacco-related research and 20% on antismoking education programs (<i>JAMA</i>. 1992;267:2721-2726). From the start, Gov Pete Wilson and the legislature, urged on by the tobacco industry and other groups, diverted increasing amounts of money from Prop 99 health education and research accounts to help pay for medical care
Sharing methods for global health research: an assessment of methodology
Authors: Trudie Lang, Kevin Marsh, Rosanna Peeling, Jeremy Farrar
Journal: The Lancet Global Health (2013)

BackgroundSetting up a clinical study can take more than 18 months and can cost millions of pounds. For many aspects of global health there is a dearth of research, yet evidence is urgently needed to address major challenges. Obtaining such data within a meaningful timeframe requires a fundamental change in the planning and setting up of research studies. Typically, protocols are developed in closed groups and often never shared. However, many operational processes in research are generic, irrespective of the disease or design. Thus, removal of duplication and sharing methods could speed up research. This research methodology project investigates whether researchers can be persuaded to share methods and if this will streamline research.MethodsThe theory of communities of practice (in which distinct specialists working on a problem collaborate to solve it) guided this project. The Global Health Network was created to enable communities of practice to form to develop protocols, exchange research instruments, and share skills. We measured uptake, effect, and benefit of the Network through surveys, questionnaires, interviews with target audiences (research teams in low-income and middle-income countries), and analysis of digital access.FindingsSince 2011, more than 60 000 researchers, nurses, technicians, and scientists from almost all low-income and middle-income countries have used the project to share research methods, knowledge, and processes. 21 specialised communities of practice have formed collaborations that are actively exchanging methods. More than 250 research guidance notes have been shared that provide specific guidance for various research methods—eg, an international respiratory disease network has released three open-access novel coronavirus protocols and groups working in maternal health are listing the samples they have stored with the invitation for others to collaborate. These qualitative and quantitative data show that these exchanges are highly beneficial for guiding and improving research operations, and that there is a willingness to share.InterpretationScientists compete for funding and publication and therefore sharing methods and knowledge can be perceived as disadvantageous. However, if use of protocols and methods developed by wide and open consensus can help to quickly gain high quality data, then better progress could be made for all and disease research could be changed to improve health.FundingBill & Melinda Gates Foundation.
Natural Childbirth.
Journal: JAMA (1933)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
ACETALDEHYDE FORMATION IN THE BODY
Journal: JAMA (1926)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Coral Dermatitis
Authors: Michael Lause, Mark Mcintyre, John Trinidad
Journal: JAMA Dermatology (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Rubella antibody persistence after immunization
Authors: K. L. Herrmann
Journal: JAMA (1982)

A comparative field trial of three live, attenuated rubella virus vaccines (Cendehill, HPV-77 DE-5, and HPV-77 DK-12) was initiated in 1969 on the islands of Kauai and Hawaii in the state of Hawaii. Following initial seroconversion rates of more than 98%, periodic serological testing of the study population was conducted to assess the durability of vaccine-induced immunity. In February 1980, ten years after the initiation of the study, 741 of the 5,153 original susceptible vaccinees were still enrolled in the study. After a drop of approximately 50% in mean hemagglutination-inhibition (HI) titer for each of the vaccine groups during the first four years following vaccination, the HI titer levels for all three groups have been generally stable between years 4 and 10. The frequency of reversion to an HI titer of less than 10 has remained less than 0.5% per year. A measurable HI antibody level has persisted in more than 97% of all vaccinees over the ten-year period. This study indicates that when potent rubella vaccine is administered properly, a high seroconversion rate and a high rate of antibody persistence should be expected. (<i>JAMA</i>1982;247:193-196)
Stenosing Tenosynovitis
Authors: G. Palmborg
Journal: Annals of the Rheumatic Diseases (1952)

<h3>Abstract</h3> In this paper, we introduce a general novel compartmental model accounting for the effects of vaccine efficacy, deployment rates and timing of initiation of deployment. It consists of compartments corresponding to susceptible, vaccinated susceptible, infectious, vaccinated infectious, active, and dead populations with various vaccine efficacies and vaccination deployment rates. We simulate different scenarios and initial conditions, and we find that the abundance and higher rate of deployment of low efficacy vaccines would lower the cumulative number of deaths in comparison to slower deployment of high efficacy vaccines. However, the latter can lower the number of active cases and achieve faster and higher herd immunity. We also forecast that, at the same daily deployment rate, the earlier introduction of vaccination schemes with lower efficacy would also lower the number of deaths with respect to a delayed introduction of high efficacy vaccines, which can however, still achieve lower numbers of infections and better herd immunity.
The Decline of an Old Amenity
Journal: JAMA (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal